Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction. Zenflow, Inc., a medical device company developing a minimally invasive treatment...
Zenflow’s $24 Million Series C Financing Round
Cellino Biotech’s $25 Million Funding
Wilson Sonsini Goodrich & Rosati represented Cellino Biotech, Inc. on the transaction. Cellino Biotech, Inc. (Cellino) announced that the Advanced Research Projects Agency for Health (ARPA-H),...
LENZ Therapeutics’ $30 Million Private Placement Financing
Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
JIXING’s Collaborations with TMS
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
Arcellx’s Expansion of Partnership with Kite
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
JURA Bio’s $16.1 Million Financing and Replay Collaboration
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
Oricell Therapeutics’ $45 Million Series B1 Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal. Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor...
Pearl Health’s $75 Million Series B
Wilson Sonsini advised a16z on the deal. Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, announced it has...
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
ATP’s Launch of Ascidian Therapeutics
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
Rivus Pharmaceuticals’ $132 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...